Form 4 for ACAD ACADIA PHARMACEUTICALS INC
Accepted 2023-04-07 00:00:00 ET · period of report 2023-04-05 · accession 0001209191-23-023865 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-04-07 | 2023-04-06 | ACAD | Teehan Brendan | EVP, COO, Head of Commercial | S - Sale+OE | $18.16 | -1,751 | 8,468 | -17% | -$31.8K |
| D | 2023-04-07 | 2023-04-05 | ACAD | Teehan Brendan | EVP, COO, Head of Commercial | M - OptEx | — | +5,024 | 10.2K | +97% | — |
| D | 2023-04-07 | 2023-04-05 | ACAD | Teehan Brendan | EVP, COO, Head of Commercial | M - OptEx | $0.00 | -5,024 | 15.1K | -25% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-04-06 | S | D | 1,751 | $18.16 | 8,468 | D | — | — | |
| 2 | Common | Common Stock | 2023-04-05 | M | A | 5,024 | — | 10,219 | D | — | — | (F1) Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. |
| 3 | Derivative | Restricted Stock Units | 2023-04-05 | M | D | 5,024 | $0.00 | 15,072 | D | — · — to — | 5,024 Common Stock | (F1) Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. (F3) The restricted stock units vest in four equal annual installments beginning April 5, 2023. |